C. J. Murray and A. D. Lopez, The Global Burden of Disease, World Health Organisation, 1996.
URL : https://hal.archives-ouvertes.fr/hal-00921564

M. Menken, T. L. Munsat, and J. F. Toole, The Global Burden of Disease Study, Archives of Neurology, vol.57, issue.3, pp.418-420, 2000.
DOI : 10.1001/archneur.57.3.418

L. I. Golbe, Neurodegeneration in the age of molecular biology, BMJ, vol.324, issue.7352, pp.1467-1468, 2002.
DOI : 10.1136/bmj.324.7352.1467

J. P. Ioannidis, T. A. Trikalinos, and M. J. Khoury, Implications of Small Effect Sizes of Individual Genetic Variants on the Design and Interpretation of Genetic Association Studies of Complex Diseases, American Journal of Epidemiology, vol.164, issue.7, pp.164-609, 2006.
DOI : 10.1093/aje/kwj259

M. Y. Wong, N. E. Day, J. A. Luan, K. P. Chan, and N. J. Wareham, The detection of gene???environment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement?, International Journal of Epidemiology, vol.32, issue.1, pp.32-51, 2003.
DOI : 10.1093/ije/dyg002

M. Garcia-closas, W. D. Thompson, and J. M. Robins, Differential Misclassification and the Assessment of Gene-Environment Interactions in Case-Control Studies, American Journal of Epidemiology, vol.147, issue.5, pp.147-426, 1998.
DOI : 10.1093/oxfordjournals.aje.a009467

A. Schatzkin and E. Slud, COMPETING RISKS BIAS ARISING FROM AN OMITTED RISK FACTOR, American Journal of Epidemiology, vol.129, issue.4, pp.850-856, 1989.
DOI : 10.1093/oxfordjournals.aje.a115199

E. Slud and D. Byar, How Dependent Causes of Death Can Make Risk Factors Appear Protective, Biometrics, vol.44, issue.1, pp.265-269, 1988.
DOI : 10.2307/2531915

A. Elbaz and A. Alperovitch, Bias in Association Studies Resulting from Gene-Environment Interactions and Competing Risks, American Journal of Epidemiology, vol.155, issue.3, pp.265-273, 2002.
DOI : 10.1093/aje/155.3.265

L. A. Farrer, L. A. Cupples, J. L. Haines, B. Hyman, W. A. Kukull et al., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium, JAMA: The Journal of the American Medical Association, vol.278, issue.16, pp.278-1349, 1997.
DOI : 10.1001/jama.278.16.1349

W. A. Rocca, S. K. Mcdonnell, K. J. Strain, J. H. Bower, J. E. Ahlskog et al., Familial aggregation of Parkinson's disease: The Mayo Clinic family study, Annals of Neurology, vol.13, issue.4, pp.56-495, 2004.
DOI : 10.1002/ana.20228

D. Twelves, K. S. Perkins, and C. , Systematic review of incidence studies of Parkinson's disease, Movement Disorders, vol.354, issue.1, pp.19-31, 2003.
DOI : 10.1002/mds.10305

A. Elbaz, J. H. Bower, D. M. Maraganore, S. K. Mcdonnell, B. J. Peterson et al., Risk tables for parkinsonism and Parkinson's disease, Journal of Clinical Epidemiology, vol.55, issue.1, pp.55-80, 2002.
DOI : 10.1016/S0895-4356(01)00425-5

M. C. De-rijk, L. J. Launer, K. Berger, M. M. Breteler, J. F. Dartigues et al., Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts, Neurologic Diseases in the Elderly Research Group, pp.21-23, 2000.

P. Martinez-martin, An introduction to the concept of ???quality of life in Parkinson???s disease???, Journal of Neurology, vol.245, issue.S1, pp.2-6, 1998.
DOI : 10.1007/PL00007733

S. A. Parashos, D. M. Maraganore, P. C. O-'brien, and W. A. Rocca, Medical services utilization and prognosis in Parkinson disease: a population-based study, Mayo Clin. Proc, pp.77-918, 2002.

H. Checkoway and L. M. Nelson, Epidemiologic Approaches to the Study of Parkinson??s Disease Etiology, Epidemiology, vol.10, issue.3, pp.327-336, 1999.
DOI : 10.1097/00001648-199905000-00023

A. Elbaz, S. K. Mcdonnell, D. M. Maraganore, K. J. Strain, D. J. Schaid et al., Validity of family history data on PD: Evidence for a family information bias, Neurology, vol.61, issue.1, pp.61-72, 2003.
DOI : 10.1212/01.WNL.0000068007.58423.C2

M. J. Farrer, Genetics of Parkinson disease: paradigm shifts and future prospects, Nature Reviews Genetics, vol.59, issue.4, pp.306-318, 2006.
DOI : 10.1038/nrg1831

A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer et al., Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology, Neuron, vol.44, issue.4, pp.601-607, 2004.
DOI : 10.1016/j.neuron.2004.11.005

L. J. Ozelius, G. Senthil, R. Saunders-pullman, E. Ohmann, A. Deligtisch et al., G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews, LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews, pp.424-425, 2006.
DOI : 10.1056/NEJMc055509

M. A. Hernan, B. Takkouche, F. Caamanoisorna, and J. J. Gestal-otero, A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease, Annals of Neurology, vol.21, issue.suppl 1, pp.52-276, 2002.
DOI : 10.1002/ana.10277

G. W. Ross and H. Petrovitch, Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson??s Disease, Drugs & Aging, vol.59, issue.6, pp.797-806, 2001.
DOI : 10.2165/00002512-200118110-00001

J. P. Galanaud, A. Elbaz, J. Clavel, J. Vidal, J. Corrèze et al., Cigarette smoking and Parkinson's disease: A case-control study in a population characterized by a high prevalence of pesticide exposure, Movement Disorders, vol.62, issue.Suppl. 2, pp.181-189, 2005.
DOI : 10.1002/mds.20307

H. Chen, S. M. Zhang, M. A. Schwarzschild, M. A. Hernan, and A. Ascherio, Survival of Parkinson's disease patients in a large prospective cohort of male health professionals, Movement Disorders, vol.59, issue.Suppl. 5, pp.1002-1007, 2006.
DOI : 10.1002/mds.20881

M. A. Menza, L. I. Golbe, R. A. Cody, and N. E. Forman, Dopamine-related personality traits in Parkinson's disease, Neurology, vol.43, issue.3, Part 1, pp.505-508, 1993.
DOI : 10.1212/WNL.43.3_Part_1.505

L. Ishihara and C. Brayne, What is the evidence for a premorbid parkinsonian personality: A systematic review, Movement Disorders, vol.46, issue.8, pp.1066-1072, 2006.
DOI : 10.1002/mds.20980

K. Wirdefeldt, M. Gatz, Y. Pawitan, and N. L. Pedersen, Risk and protective factors for Parkinson's disease: A study in Swedish twins, Annals of Neurology, vol.35, issue.1, pp.27-33, 2005.
DOI : 10.1002/ana.20307

C. M. Tanner, S. M. Goldman, D. A. Aston, R. Ottman, J. Ellenberg et al., Smoking and Parkinson's disease in twins, Neurology, vol.58, issue.4, pp.581-588, 2002.
DOI : 10.1212/WNL.58.4.581

P. Hantraye, E. Brouillet, R. Ferrante, S. Palfi, R. Dolan et al., Inhibition of neuronal nitric oxide synthase prevents MPTP???induced parkinsonism in baboons, Nature Medicine, vol.92, issue.9, pp.1017-1021, 1996.
DOI : 10.1006/exnr.1993.1006

S. Hunot, F. Boissiere, B. Faucheux, B. Brugg, A. Mouatt-prigent et al., Nitric oxide synthase and neuronal vulnerability in parkinson's disease, Neuroscience, vol.72, issue.2, pp.355-363, 1996.
DOI : 10.1016/0306-4522(95)00578-1

C. Levecque, A. Elbaz, J. Clavel, F. Richard, J. Vidal et al., Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study, Human Molecular Genetics, vol.12, issue.1, pp.12-79, 2003.
DOI : 10.1093/hmg/ddg009

S. Hague, T. Peuralinna, J. Eerola, O. Hellstrom, P. J. Tienari et al., Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease, Neurology, vol.62, issue.4, pp.635-636, 2004.
DOI : 10.1212/01.WNL.0000110191.38152.29

. Scott, NOS2A and the modulating effect of cigarette smoking in Parkinson's disease, Ann. Neurol, vol.60, pp.366-373, 2006.

S. Pogun, S. Demirgoren, D. Taskiran, L. Kanit, O. Yilmaz et al., Nicotine modulates nitric oxide in rat brain, European Neuropsychopharmacology, vol.10, issue.6, pp.463-472, 2000.
DOI : 10.1016/S0924-977X(00)00116-4

E. A. Mazzio, M. G. Kolta, R. R. Reams, and K. F. Soliman, Inhibitory Effects of Cigarette Smoke on Glial Inducible Nitric Oxide Synthase and Lack of Protective Properties Against Oxidative Neurotoxins In Vitro, NeuroToxicology, vol.26, issue.1, pp.49-62, 2005.
DOI : 10.1016/j.neuro.2004.07.005

J. W. Langston, P. Ballard, J. W. Tetrud, and I. Irwin, Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis, Science, vol.219, issue.4587, pp.979-980, 1983.
DOI : 10.1126/science.6823561

A. Priyadarshi, S. A. Khuder, E. A. Schaub, and S. Shrivastava, A meta-analysis of Parkinson's disease and exposure to pesticides, Neurotoxicology, vol.21, pp.435-440, 2000.

A. Priyadarshi, S. A. Khuder, E. A. Schaub, and S. S. Priyadarshi, Environmental Risk Factors and Parkinson's Disease: A Metaanalysis, Environmental Research, vol.86, issue.2, pp.122-127, 2001.
DOI : 10.1006/enrs.2001.4264

H. H. Liou, M. C. Tsai, C. J. Chen, J. S. Jeng, Y. C. Chang et al., Environmental risk factors and Parkinson's disease: A case-control study in Taiwan, Neurology, vol.48, issue.6, pp.1583-1588, 1997.
DOI : 10.1212/WNL.48.6.1583

A. Seidler, W. Hellenbrand, B. P. Robra, P. Vieregge, P. Nischan et al., Possible environmental, occupational, and other etiologic factors for Parkinson's disease: A case-control study in Germany, Neurology, vol.46, issue.5, pp.1275-1284, 1996.
DOI : 10.1212/WNL.46.5.1275

T. P. Brown, P. C. Rumsby, A. C. Capleton, L. Rushton, and L. S. Levy, Pesticides and Parkinson???s Disease???Is There a Link?, Environmental Health Perspectives, vol.114, issue.2, pp.156-164, 2006.
DOI : 10.1289/ehp.8095
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1367825

A. Ascherio, H. Chen, M. G. Weisskopf, E. J. O-'reilly, M. L. Mc-cullough et al., Pesticide exposure and risk for Parkinson's disease, Annals of Neurology, vol.15, issue.2, pp.60-197, 2006.
DOI : 10.1002/ana.20904

I. Baldi, P. Lebailly, B. Mohammed-brahim, L. Letenneur, J. Dartigues et al., Neurodegenerative Diseases and Exposure to Pesticides in the Elderly, American Journal of Epidemiology, vol.157, issue.5, pp.409-414, 2003.
DOI : 10.1093/aje/kwf216

W. F. Stewart and P. A. Stewart, Occupational case-control studies: I. Collecting information on work histories and work-related exposures, American Journal of Industrial Medicine, vol.5, issue.3, pp.297-312, 1994.
DOI : 10.1002/ajim.4700260304

D. G. Lecouteur, A. J. Mclean, M. C. Taylor, B. L. Woodham, and P. G. , Board, Pesticides and Parkinson's disease, Biomed. Pharmacother, pp.53-122, 1999.

S. J. Mccann, S. M. Pond, K. M. James, and D. G. Lecouteur, The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis, Journal of the Neurological Sciences, vol.153, issue.1, pp.50-53, 1997.
DOI : 10.1016/S0022-510X(97)00179-2

Y. Deng, B. Newman, M. P. Dunne, P. A. Silburn, and G. D. Mellick, Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease, Annals of Neurology, vol.55, issue.6, p.55, 2004.
DOI : 10.1002/ana.20143

R. Kortekaas, K. L. Leenders, J. C. Van-oostrom, W. Vaalburg, J. Bart et al., Blood-brain barrier dysfunction in parkinsonian midbrain in vivo, Annals of Neurology, vol.14, issue.2, pp.176-179, 2005.
DOI : 10.1002/ana.20369

T. Furuno, M. T. Landi, M. Ceroni, N. Caporaso, I. Bernucci et al., Expression polymorphism of the blood???brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease, Pharmacogenetics, vol.12, issue.7, pp.529-534, 2002.
DOI : 10.1097/00008571-200210000-00004

M. Drozdzik, M. Bialecka, K. Mysliwiec, K. Honczarenko, J. Stankiewicz et al., Polymorphism in the P-glycoprotein drug transporter MDR1 gene, Pharmacogenetics, vol.13, issue.5, pp.259-263, 2003.
DOI : 10.1097/00008571-200305000-00004

A. Elbaz, F. Dutheil, A. Alpérovitch, M. Loriot, and C. Tzourio, Case-control study of the MDR1 gene in Parkinson disease, Mov. Disord, vol.21, issue.15, p.405, 2006.

S. N. Kelada, H. Checkoway, S. L. Kardia, C. S. Carlson, P. Costa-mallen et al., 5' and 3' region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study, Human Molecular Genetics, vol.15, issue.20, pp.15-3055, 2006.
DOI : 10.1093/hmg/ddl247

J. R. Richardson, W. M. Caudle, M. Wang, E. D. Dean, K. D. Pennell et al., Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease, The FASEB Journal, vol.20, issue.10, pp.1695-1697, 2006.
DOI : 10.1096/fj.06-5864fje

W. M. Caudle, J. R. Richardson, M. Wang, and G. W. Miller, Perinatal Heptachlor Exposure Increases Expression of Presynaptic Dopaminergic Markers in Mouse Striatum, NeuroToxicology, vol.26, issue.4, pp.721-728, 2005.
DOI : 10.1016/j.neuro.2004.09.003

K. Ritchie and S. Lovestone, The dementias, The Lancet, vol.360, issue.9347, pp.1759-1766, 2002.
DOI : 10.1016/S0140-6736(02)11667-9

R. Mayeux, Genetic Epidemiology of Alzheimer Disease, Alzheimer Disease & Associated Disorders, vol.20, issue.Supplement 2, pp.58-62, 2006.
DOI : 10.1097/00002093-200607001-00008

R. Mayeux, M. Sano, J. Chen, T. Tatemichi, and Y. Stern, Risk of Dementia in First-Degree Relatives of Patients With Alzheimer's Disease and Related Disorders, Archives of Neurology, vol.48, issue.3, pp.48-269, 1991.
DOI : 10.1001/archneur.1991.00530150037014

C. Dufouil, C. Tzourio, C. Brayne, C. Berr, P. Amouyel et al., Influence of Apolipoprotein E Genotype on the Risk of Cognitive Deterioration in Moderate Drinkers and Smokers, Epidemiology, vol.11, issue.3, pp.280-284, 2000.
DOI : 10.1097/00001648-200005000-00009

M. N. Haan, L. Shemanski, W. J. Jagust, T. A. Manolio, and L. Kuller, The role of APOE epsilon 4 in modulating effects of other risk factors for cognitive decline in elderly persons, J. Am. Med. Assoc, pp.282-322, 1999.

L. Zhu, L. Fratiglioni, Z. C. Guo, H. Basun, E. H. Corder et al., Incidence of Dementia in Relation to Stroke and the Apolipoprotein E ??4 Allele in the Very Old : Findings From a Population-Based Longitudinal Study, Stroke, vol.31, issue.1, pp.53-60, 2000.
DOI : 10.1161/01.STR.31.1.53

K. Yaffe, M. Haan, A. Byers, C. Tangen, and L. Kuller, Estrogen use, APOE, and cognitive decline: Evidence of gene-environment interaction, Neurology, vol.54, issue.10, pp.1949-1953, 2000.
DOI : 10.1212/WNL.54.10.1949

R. Peila, L. R. White, H. Petrovich, K. Masaki, G. W. Ross et al., Joint Effect of the APOE Gene and Midlife Systolic Blood Pressure on Late-Life Cognitive Impairment: The Honolulu-Asia Aging Study Editorial Comment: The Honolulu-Asia Aging Study, Stroke, vol.32, issue.12, pp.2882-2887, 2001.
DOI : 10.1161/hs1201.100392

A. Ruitenberg, J. C. Vanswieten, J. C. Witteman, K. M. Mehta, C. M. Vanduijn et al., Alcohol consumption and risk of dementia: the Rotterdam Study, The Lancet, vol.359, issue.9303, pp.281-286, 2002.
DOI : 10.1016/S0140-6736(02)07493-7

R. Peila, B. L. Rodriguez, and L. J. Launer, Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies: The Honolulu-Asia Aging Study, Diabetes, vol.51, issue.4, pp.1256-1262, 2002.
DOI : 10.2337/diabetes.51.4.1256

. Grobbee, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, Lancet, vol.349, pp.151-154, 1997.

L. J. Podewils, E. Guallar, L. H. Kuller, L. P. Fried, O. L. Lopez et al., Physical Activity, APOE Genotype, and Dementia Risk: Findings from the Cardiovascular Health Cognition Study, American Journal of Epidemiology, vol.161, issue.7, pp.161-639, 2005.
DOI : 10.1093/aje/kwi092

G. P. Jarvik, E. Wijsman, W. A. Kukull, G. D. Schellenberg, C. Yu et al., Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: A case-control study, Neurology, vol.45, issue.6, pp.1092-1096, 1995.
DOI : 10.1212/WNL.45.6.1092

C. Dufouil, F. Richard, N. Fievet, J. F. Dartigues, K. Ritchie et al., APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study, Neurology, vol.64, issue.9, pp.1531-1538, 2005.
DOI : 10.1212/01.WNL.0000160114.42643.31
URL : https://hal.archives-ouvertes.fr/inserm-00175952

V. Chandra and R. Pandav, Gene-Environment Interaction in Alzheimer???s Disease:A Potential Role for Cholesterol, Neuroepidemiology, vol.17, issue.5, pp.225-232, 1998.
DOI : 10.1159/000026175

M. Kivipelto, E. L. Helkala, M. P. Laakso, T. Hanninen, M. Hallikainen et al., Apolipoprotein E ??4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease, Annals of Internal Medicine, vol.137, issue.3, pp.149-155, 2002.
DOI : 10.7326/0003-4819-137-3-200208060-00006

K. Hall, J. Murrell, A. Ogunniyi, M. Deeg, O. Baiyewu et al., Cholesterol, APOE genotype, and Alzheimer disease: An epidemiologic study of Nigerian Yoruba, Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba, pp.223-227, 2006.
DOI : 10.1212/01.wnl.0000194507.39504.17

R. M. Evans, C. L. Emsley, S. Gao, A. Sahota, K. S. Hall et al., Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: A population-based study of African Americans, Neurology, vol.54, issue.1, pp.240-242, 2000.
DOI : 10.1212/WNL.54.1.240

D. M. Maraganore, M. De-andrade, A. Elbaz, M. J. Farrer, J. P. Ioannidis et al., Collaborative analysis of the alpha-synuclein gene promoter variability and Parkinson's disease, J. Am. Med. Assoc, pp.296-661, 2006.

A. Elbaz, L. M. Nelson, H. Payami, J. P. Ioannidis, B. K. Fiske et al., Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study, The Lancet Neurology, vol.5, issue.11, pp.917-923, 2006.
DOI : 10.1016/S1474-4422(06)70579-8